tPA for Stroke - Zivin, Justin A; Simmons, John Galbraith
55,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in über 4 Wochen
payback
28 °P sammeln
  • Gebundenes Buch

Authors Zivin and Simmons explain how the remarkable drug tPA came to be used for stroke survivors, the drug's infancy and childhood within the pharmaceutical giant Genentech, and its eventual marginalization due to a convergence of unfortunate political, fiscal, and medical circumstances.

Andere Kunden interessierten sich auch für
Produktbeschreibung
Authors Zivin and Simmons explain how the remarkable drug tPA came to be used for stroke survivors, the drug's infancy and childhood within the pharmaceutical giant Genentech, and its eventual marginalization due to a convergence of unfortunate political, fiscal, and medical circumstances.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Autorenporträt
Justin Zivin is a Professor of Neurosciences at the University of California San Diego. He holds both MD and PhD degrees from Northwestern University, and was trained as a neurologist at the University of California San Francisco. For more than thirty years he has conducted research in acute stroke therapy both for basic science studies and clinical trials. He has been continuously funded for this research by federal agencies since 1979. John Galbraith Simmons studied philosophy at Northwestern University, graduating with honors, and also holds a degree in developmental studies from Long Island University. He has published four novels, written for television and film, and is also the author of The Scientific 100: A Ranking of the Most Influential Scientists, Past and Present and Doctors and Discoveries: Lives That Created Today's Medicine. He lives in New York and Paris.